Printer Friendly

COMPANY INFORMATION
IntelGenx Technologies Corp. 6425 Abrams Saint-Laurent, QC H4S 1X9 Tel: (514) 331-7440 Fax: (514) 331-0436 Contact Name Ingrid Zerbe Industry Biotechnology		Key Executives Horst G. Zerbe, CEO Paul Simmons, CFO Develops and commercializes novel, orally administered immediate release and controlled-release drug delivery products for the branded and generic pharmaceutical markets.
FP ADVISOR COVERAGE IntelGenx Technologies Corp. • FP Corporate Surveys • FP Directory of Directors • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX-VEN/IGX $0.58 $0.76 $0.37 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 23,945 n.a. US$-0.07 Sept. 30/09 n.a. n.a. n.a. $19,187
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08A 12m Dec. 31/07A 12m Dec. 31/06A US$000s US$000s US$000s Operating revenue 946 835 262 Net income (2,806) (1,101) (781) Total assets 1,622 1,271 651 US$ US$ US$ Earnings per share* (0.14) (0.07) (0.05) % % % Return on equity (1461.46) (407.78) n.m.   * Common A Reported in accordance with U.S. GAAP

COMPANY NEWS

Results for 'IntelGenx Technologies Corp.' from past 30 days: No hits. (Links are to articles.)